ID   U2OS-ATRkd
AC   CVCL_A5LZ
SY   U2OS/ATRkd; U2OS ATRkd
DR   BTO; BTO:0003696
DR   Wikidata; Q107117180
RX   PubMed=11481475;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: HGNC; 882; ATR (with p.Asp2494Glu = ATRkd).
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0042 ! U2OS
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=11481475; DOI=10.1073/pnas.161281798;
RA   Nghiem P., Park P.K., Kim Y.-S., Vaziri C., Schreiber S.L.;
RT   "ATR inhibition selectively sensitizes G1 checkpoint-deficient cells
RT   to lethal premature chromatin condensation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9092-9097(2001).
//